Form 4: Terns Pharmaceuticals Director Ann Elizabeth Taylor Acquires Stock Options
SEC Form 4 Filing
Director Ann Elizabeth Taylor acquired 32,000 stock options in Terns Pharmaceuticals on June 10, 2024, at an exercise price of $6.99.
Summary
- On June 10, 2024, Ann Elizabeth Taylor, a director of Terns Pharmaceuticals, acquired 32,000 stock options.
- The exercise price for these options is $6.99 per share.
- The options vest fully on the earlier of the first anniversary of the grant date or immediately prior to the next Annual Meeting following the grant date.
- The options expire on June 9, 2034.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock option acquisition by a director. It doesn't inherently indicate positive or negative sentiment.
Industry Context
This is a standard disclosure related to insider transactions, common in publicly traded companies. It provides transparency into the trading activities of company insiders.
Stakeholder Impact
- Shareholders are informed about the stock option grant to a director, providing transparency into potential dilution and executive compensation.
Key Dates
| Date | Description |
|---|---|
| 06/10/2024 | Date of stock option grant and transaction. |
| 06/09/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.